AstraZeneca | PCDS Wales | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

Company Profile

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit AstraZeneca’s website to learn more about Forxiga

This resource page and the materials included have been organised and funded by AstraZeneca

Value beyond glycaemic control during unprecedented times


Play Video

Dr John Wilding

Early treatment of Type 2 diabetes during unprecedented times

Play Video

Dr Marc Evans

Value beyond glycaemic control during unprecedented times

PDF Download

Forxiga for you: Patient information booklet post prescription

Play Video

Dr Vinesh Soba

Value beyond glycaemic control during unprecedented times

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to AstraZeneca on 0800 783 0033


Date of prep: October 2020

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.